3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
5
Colorectal Neoplasms
3
Neoplasms
2
Lung Neoplasms
2
Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma
1
Melanoma
1
Lymphoma
1
Leukemia
1
Hematologic Neoplasms
1
Gastrointestinal Stromal Tumors
1
Esophageal Squamous Cell Carcinoma
1
EGFR-mutant Non-small Cell Lung Cancer
1
Adenocarcinoma of Lung
1
Interventions
Azacitidine
3
Polymerase Chain Reaction
2
Counseling
2
Bupropion
2
tanespimycin
1
sargramostim
1
ruxolitinib
1
rucaparib
1
ribociclib
1
pembrolizumab
1
motexafin gadolinium
1
incomplete Freund's adjuvant
1
cc-486
1
abiraterone
1
Zinc Oxide
1
Varenicline
1
Uncertainty
1
Tobacco Use Cessation Devices
1
Tissue Banks
1
Tinzaparin
1
Radiotherapy
1
Psychosocial Intervention
1
Psychiatric Rehabilitation
1
Paclitaxel
1
Observation
1
Nicotine Replacement Therapy
1
Nicotine
1
Methylprednisolone
1
Melphalan
1
Interleukin-15
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia
×
ribociclib
×
Thoracic
×
Clear all
NCT02187783
2019-07-18
SIGNATURE
Novartis
Phase 2
Completed
106 enrolled
16 charts